JP7532257B2 - ポリオーマウイルス複製の阻害 - Google Patents

ポリオーマウイルス複製の阻害 Download PDF

Info

Publication number
JP7532257B2
JP7532257B2 JP2020545683A JP2020545683A JP7532257B2 JP 7532257 B2 JP7532257 B2 JP 7532257B2 JP 2020545683 A JP2020545683 A JP 2020545683A JP 2020545683 A JP2020545683 A JP 2020545683A JP 7532257 B2 JP7532257 B2 JP 7532257B2
Authority
JP
Japan
Prior art keywords
seq
mrna
oligonucleotide
nucleobases
polyomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524730A5 (enExample
JP2021524730A (ja
Inventor
デル ビアー、エーリヒ ピーター ファン
ゾンネフェルト、アントン ヤン ファン
プリンス、ユリエン
Original Assignee
アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61563209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7532257(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム filed Critical アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム
Publication of JP2021524730A publication Critical patent/JP2021524730A/ja
Publication of JP2021524730A5 publication Critical patent/JP2021524730A5/ja
Priority to JP2024123185A priority Critical patent/JP2024156786A/ja
Application granted granted Critical
Publication of JP7532257B2 publication Critical patent/JP7532257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020545683A 2018-03-02 2019-03-01 ポリオーマウイルス複製の阻害 Active JP7532257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024123185A JP2024156786A (ja) 2018-03-02 2024-07-30 ポリオーマウイルス複製の阻害

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18159797.2 2018-03-02
EP18159797 2018-03-02
PCT/NL2019/050131 WO2019168402A1 (en) 2018-03-02 2019-03-01 Inhibition of polyomavirus replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024123185A Division JP2024156786A (ja) 2018-03-02 2024-07-30 ポリオーマウイルス複製の阻害

Publications (3)

Publication Number Publication Date
JP2021524730A JP2021524730A (ja) 2021-09-16
JP2021524730A5 JP2021524730A5 (enExample) 2022-02-16
JP7532257B2 true JP7532257B2 (ja) 2024-08-13

Family

ID=61563209

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545683A Active JP7532257B2 (ja) 2018-03-02 2019-03-01 ポリオーマウイルス複製の阻害
JP2024123185A Pending JP2024156786A (ja) 2018-03-02 2024-07-30 ポリオーマウイルス複製の阻害

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024123185A Pending JP2024156786A (ja) 2018-03-02 2024-07-30 ポリオーマウイルス複製の阻害

Country Status (7)

Country Link
US (2) US11661602B2 (enExample)
EP (1) EP3759221A1 (enExample)
JP (2) JP7532257B2 (enExample)
CN (2) CN112218949B (enExample)
BR (1) BR112020017949A2 (enExample)
CA (1) CA3092817A1 (enExample)
WO (1) WO2019168402A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024156786A (ja) * 2018-03-02 2024-11-06 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム ポリオーマウイルス複製の阻害

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316802A (en) * 2022-05-06 2025-01-01 Academisch Ziekenhuis Leiden Oligonucleotide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535039A (ja) 2006-04-28 2009-10-01 アルナイラム ファーマシューティカルズ インコーポレイテッド Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
WO2017100431A2 (en) 2015-12-09 2017-06-15 Excision Biotherapeutics, Inc. Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2007536937A (ja) * 2004-05-12 2007-12-20 カメル・カリーリ 霊長類ポリオーマウイルス遺伝子のｓｉＲＮＡ干渉用組成物および方法
US7892795B2 (en) * 2005-08-02 2011-02-22 Focus Diagnostics, Inc. Methods and compositions for detecting BK virus
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2008077511A1 (en) * 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
US20110118340A1 (en) * 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
US20090246754A1 (en) * 2008-02-19 2009-10-01 Intelligent Mdx Optimized probes and primers and methods of using same for the detection and quantitation of bk virus
CN102363818B (zh) * 2011-06-28 2013-01-02 同昕生物技术（北京）有限公司 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒
WO2013119979A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Methods and compositions for modulating factor vii expression
CN103276107B (zh) * 2013-05-13 2014-11-19 中国医学科学院病原生物学研究所 一种高灵敏度检测和鉴定人多瘤病毒的方法
EP3047023B1 (en) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting jc virus (jcv)
ES2903394T3 (es) * 2015-12-14 2022-04-01 Cold Spring Harbor Laboratory Composiciones para el tratamiento de la retinitis pigmentosa 13
US11096956B2 (en) * 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2019168402A1 (en) * 2018-03-02 2019-09-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Inhibition of polyomavirus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535039A (ja) 2006-04-28 2009-10-01 アルナイラム ファーマシューティカルズ インコーポレイテッド Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
WO2017100431A2 (en) 2015-12-09 2017-06-15 Excision Biotherapeutics, Inc. Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024156786A (ja) * 2018-03-02 2024-11-06 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム ポリオーマウイルス複製の阻害

Also Published As

Publication number Publication date
CN112218949A (zh) 2021-01-12
WO2019168402A1 (en) 2019-09-06
CN119823988A (zh) 2025-04-15
JP2024156786A (ja) 2024-11-06
US12480122B2 (en) 2025-11-25
US20210010004A1 (en) 2021-01-14
CA3092817A1 (en) 2019-09-06
CN112218949B (zh) 2025-02-11
EP3759221A1 (en) 2021-01-06
BR112020017949A2 (pt) 2020-12-22
US11661602B2 (en) 2023-05-30
US20230212580A1 (en) 2023-07-06
JP2021524730A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
JP6851201B2 (ja) ポンペ病の治療に有用なアンチセンスオリゴヌクレオチド
JP2024156786A (ja) ポリオーマウイルス複製の阻害
EP2794880B1 (en) Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
WO2009023525A2 (en) Methods of modulating mesenchymal stem cell differentiation
US9518261B2 (en) Modulation of enhancer RNA mediated gene expression
EP1871426A2 (en) Small activating rna molecules and methods of use
WO2012006181A2 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2013155330A1 (en) Compositions and methods for characterizing and treating muscular dystrophy
Chen et al. Neuronal miR-138 represses HSV-2 lytic infection by regulating viral and host genes with mechanistic differences from HSV-1
WO2017156591A1 (en) Osteoarthritis mirnas
US20210290653A1 (en) Modulation of lnc05 expression
US11058709B1 (en) Methods of treating breast cancer
JP2023542033A (ja) 脂肪肝疾患を治療する方法
HK40118055A (zh) 多瘤病毒复制的抑制
CN111560437A (zh) 用于预测口腔鳞癌的生物标志物及其在治疗中的应用
CN111575381A (zh) 生物标志物的新用途
US20250136942A1 (en) Methods to accelerate stem cell differentiation to cardiomyocytes
Lyu et al. CRISPR/Cas9-based knockout of miR-487b-3p accelerates the cell proliferation of primary goat myoblast by relieving its inhibition of IRS1
KR20250017212A (ko) 올리고뉴클레오타이드
WO2024251244A1 (zh) 多核苷酸、药物组合物及其用途
JP2024516168A (ja) がんを治療するための組成物および方法
HK40094245A (zh) 治疗脂肪肝病的方法
WO2021072163A1 (en) Compositions and methods for reprogramming age-restricted non-neuronal cells
Widmark Author CRediT Statement
WO2017189927A2 (en) Increasing rnai efficiency through single nucleotide mismatches

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210322

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157